Çocukluk çağı akut lenfoblastik lösemisinde tedavinin ortalama eritrosit hacimleri üzerine etkisi

Abstract

T Th he e e ef ff fe ec ct t o of f t tr re ea at tm me en nt t o of f a ac cu ut te e l ly ym mp ph ho ob bl la as st ti ic c l le eu uk ke em mi ia a o on n m me ea an n e er ry yt th hr ro oy yt te e v vo ol lu um me e i in n c ch hi il ld dr re en n T Ti ir ra aj je e C Ce el lk ka an n, , N Ni ih ha al l Ö Öz zd de em mi ir r , , Z Ze ek ke er ri iy ya a Material and Method:One hundred-twenty-five children with ALL were included in this retrospective study. The MCV values of the patients (age 1-15 years, 83 boys, 42 girls) at diagnosis, at induction/consolidation chemotherapy and after maintenance treatment were evaluated. Results:The MCV values of the patients at diagnosis, at induction/consolidation chemotherapy and after maintenance treatment were 78,5+3,9 fl; 89,1+6,8 fl and 95,6+3,8 fl, respectively. On follow-up, MCV values were found to decrease with a mean of 1 fl per month after chemotherapy. The results of 15 relapsed patients were compared with results of 110 patients without relapse; there was no statistically significant difference in MCV values ( p>0.05).Conclusions: MCV was not found to be a significant parameter in relation to prognosis and relapse in children with ALL.

Significant erythroid megaloblastic changes in patients treated with allopurinol during maintenance chemotherapy for acute lymphoblastic leukemia

“…7 As such, mean corpuscular volumes (MCVs) are generally increased during maintenance therapy, with an average MCV at the end of maintenance reported to be 95.6 ± 3.8 fL. 8 However, this patient's degree of macrocytosis (MCV > 115 fL) was well outside normally observed levels.…”

Acute complications observed during intensive chemotherapy in pediatric patients with acute lymphoblastic leukemia: Single-center experience

“…Acute lymphoblastic leukemia (ALL) is the most common malignancy in childhood and constitutes 25–30% of all malignancies under 15 years of age. Its annual incidence is 4/100,000 in the USA, and it is 1.5/100,000 in Turkiye according to the Ministry of Health data [ 1 , 2 ]. By identifying risk factors determining the prognosis, and using risk-based treatment modalities, the success rate in treatment has exceeded 90% in our country as well as in developed countries [ 3 ].…”